NEW YORK (GenomeWeb) – PositiveID today announced an agreement with an unidentified institutional investor for $2.4 million in financing. 

Under the terms of the deal, PositiveID will issue a series of 4 percent original issue discount senior secured convertible promissory notes to the investor during a six-month period in a series of six notes. The investor has the right to convert the notes into PositiveID's common shares at a fixed conversion price of $.028 per share, the Delray Beach, Florida-based firm said. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.